Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784028 | 0.82 | MAPT (0.53) | MAPTMAPK1TP53THRB | |
| SCHEMBL19235492 | 0.79 | GAA (0.51) | — | |
| SCHEMBL8312487 | 0.73 | KCNQ3 (0.56) | MAPTTHRB | |
| SCHEMBL16562094 | 0.72 | MAPT (0.69) | MAPTTP53THRB | |
| SCHEMBL13354673 | 0.71 | — | — | |
| SCHEMBL29334955 | 0.71 | EPHX2 (0.61) | EPHX2NR1H4 | |
| SCHEMBL6783572 | 0.70 | P2RX7 (0.52) | — | |
| SCHEMBL6784302 | 0.70 | LMNA (0.48) | — | |
| SCHEMBL6783181 | 0.70 | — | — | |
| SCHEMBL1503985 | 0.70 | NPC1 (0.49) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776963-B2 | Small molecule CD4 mimetics and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-10-03 | — | — | US | disclosed |
| US-20120122834-A1 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010053583-A2 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | DANA FARBER CANCER INSTITUTE (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122834-A1 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | CD4, CCR1, RORC | MAPT 4771/4885MAPK1 3896/4885TP53 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.